Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy

Table 2

BMD and FRAX stratified by presence of vertebral fracture.

	No vertebral fracture							Vertebral fracture
	n = 56							n = 22
Variable	Median	Mean	SD	Range				Median	Mean	SD	Range			P-value*
BMD, femoral neck	0.7	0.7	0.1	0.5–1.0				0.7	0.7	0.1	0.5–0.9			0.34
T score, femoral neck	−1.8	−1.9	0.7	−3.3–−0.7				−2.2	−2.0	0.8	−3.4–−0.6			0.33
BMD, total hip	0.9	0.9	0.1	0.6–1.2				0.8	0.8	0.2	0.5–1.2			0.22
T score, total hip	−1.2	−1.3	0.9	−3.0–0.3				−1.4	−1.5	1.1	−3.7–0.0			0.51
BMD, lumbar spine	1.0	1.0	0.2	0.8–1.6				0.9	0.9	0.2	0.5–1.3			0.11
T score, lumbar spine	−1.1	−0.9	1.6	−4.0–4.6				−1.8	−1.6	1.8	−5.2–2.1			0.10
FRAX (Osteo) without BMD (%)	9.3	10.8	6.2	1.8–33.0				15.0	16.0	6.8	6.8–31.0			0.001
FRAX (Hip) without BMD (%)	4.0	5.5	4.8	0.1–24.0				6.8	8.1	6.0	1.7–25.0			0.03
FRAX (Osteo) with BMD (%)	7.5	9.5	6.9	1.9–33.0				11.0	14.0	7.8	5.4–41.0			0.002
FRAX (Hip) with BMD (%)	3.0	4.5	5.1	0.1–28.0				4.5	6.6	7.1	1.1–36.0			0.03

* P values are from the Wilcoxon rank sum test.
BMD measurements are in g/cm².